# Gecacitinib

Source: https://onco.cc/drugs/gecacitinib/  
OnCo record `gecacitinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Gecacitinib is an oral kinase inhibitor from Suzhou Zelgen Biopharmaceuticals Co.,Ltd, in registered phase 2 trials for cervical cancer.

## Summary

Gecacitinib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, in cervical cancer. A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Oral kinase inhibitor
- Mechanism: A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below.

## Sources

- ClinicalTrials.gov: trials of Gecacitinib: https://clinicaltrials.gov/search?intr=Gecacitinib

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- companies: [Suzhou Zelgen Biopharmaceuticals](https://onco.cc/companies/zelgen/)
- trials: [Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06903377/), [Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer](https://onco.cc/trials/nct07080216/), [Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma](https://onco.cc/trials/nct06883526/)

---
JSON: https://onco.cc/api/v1/entities/gecacitinib.json